Medpace (MEDP) Competitors

IQVIA (NYSE:IQV) and Medpace (NASDAQ:MEDP) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, community ranking, risk, analyst recommendations, earnings and institutional ownership.

Do insiders & institutionals have more ownership in IQV or MEDP?

89.6% of IQVIA shares are owned by institutional investors. Comparatively, 78.0% of Medpace shares are owned by institutional investors. 1.6% of IQVIA shares are owned by insiders. Comparatively, 20.3% of Medpace shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Does the media refer more to IQV or MEDP?

In the previous week, IQVIA had 17 more articles in the media than Medpace. MarketBeat recorded 33 mentions for IQVIA and 16 mentions for Medpace. IQVIA's average media sentiment score of 0.93 beat Medpace's score of 0.69 indicating that IQVIA is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IQVIA	22 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive
Medpace	9 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is IQV or MEDP more profitable?

Medpace has a net margin of 19.17% compared to IQVIA's net margin of 8.91%. Medpace's return on equity of 51.48% beat IQVIA's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IQVIA	8.91%	28.81%	7.02%
Medpace	19.17%	51.48%	20.47%

Do analysts rate IQV or MEDP?

IQVIA currently has a consensus target price of $251.22, suggesting a potential upside of 31.57%. Medpace has a consensus target price of $381.44, suggesting a potential upside of 11.93%. Given IQVIA's stronger consensus rating and higher probable upside, equities research analysts plainly believe IQVIA is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IQVIA	0 Sell rating(s)	3 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.90
Medpace	0 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.45

Which has more risk & volatility, IQV or MEDP?

IQVIA has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500. Comparatively, Medpace has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500.

Does the MarketBeat Community prefer IQV or MEDP?

IQVIA received 328 more outperform votes than Medpace when rated by MarketBeat users. Likewise, 68.41% of users gave IQVIA an outperform vote while only 63.54% of users gave Medpace an outperform vote.

Company	Underperform	Outperform
IQVIA	Outperform Votes 680 68.41%	Underperform Votes 314 31.59%
Medpace	Outperform Votes 352 63.54%	Underperform Votes 202 36.46%

Which has higher earnings and valuation, IQV or MEDP?

IQVIA has higher revenue and earnings than Medpace. IQVIA is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IQVIA	$15.41B	2.18	$1.37B	$7.50	25.46
Medpace	$2.11B	4.92	$404.39M	$12.63	26.98

Summary

IQVIA beats Medpace on 12 of the 19 factors compared between the two stocks.